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Background. Normal physiological properties of skin, one of the
primary organs affected in SSc, depends on collagen Types I (COL I),
III (COLIII) and V (COLV) assembly forming heterotypic fibres. COLV
regulates fibril diameter and loss of this function could result in tissue
fibrosis. In this way, our aim was to evaluate the histological and
molecular profiles of COLI, COLIII and COLV in SSc skin and its
correlation with skin thickening and disease activity.
Methods. Skin biopsies of 18 patients (5 at early and 13 at late disease
stage) and 10 healthy controls were studied. Assessment of skin
thickening was performed using the modified Rodnan skin score
(MRSS) and disease activity was calculated by Valentini Disease
Activity Index. Quantification of COLI, COLIII and COLV was evaluated
by histomorphometry in dermis and quantitative RT–PCR in dermal
fibroblast culture.
Results. A higher expression of abnormal COLV was observed in
dermis of patients with early disease when compared with control
group and late disease. The COLIII content was also higher in early
SSc when compared with healthy controls and late SSc. On the other
hand, the amount of COLI was higher in late disease when compared
with control and early SSc. A positive correlation between COLV and
MRSS (r¼ 0.42, P¼0.04) as well as disease activity (r¼0.45, P¼ 0.03)
was observed, but there was no correlation between COLI and COLIII
expression and these parameters. COLV a-1 and COLV a-2, as well as
COLI a-1 and COLIII a-1 mRNA expression were higher in SSc when
compared with control group.
Conclusion. We found increased COLIII and COLV deposition in
early SSc and increased COLI expression in late SSc indicating that
collagen remodelling in SSc is a dynamic process. The fact that
abnormal COLV expression decreases in later disease stages could
explain why skin thickening sometimes improves spontaneously with
time. Besides, COLV is correlated to MRSS and disease activity.
These findings include COLV as an important regulator of cutaneous
thickness in SSc and may add this protein as a new target for future
treatments.
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Objective. To investigate the ultrasonographic features of tendons
and surrounding structures in patients with SSc.
Methods. Fifty-five SSc patients (27 with dcSSc, 28 with lcSSc)
and 30 healthy control subjects were recruited. Tendon involvement
was investigated by clinical examination and ultrasonography (with
a General Electric Logiq 5 PRO using a 7–12 MHz linear array
transducer) at MCP areas (extensor and flexor tendons), wrists
(extensor and flexor tendons), knees (patellar), ankles (anterior,
posterior, medial and lateral).
Results. Clinical examination revealed tenosynovitis in 11 SSc
patients (8 lcSSc and 3 dcSSc) and no control subject. Tendon friction
rubs (TFRs) were detected in 12 dcSSc patients. Two dcSSc patients
presented both findings at the same tendons. US revealed tenosyno-
vitis in 21 patients (including the 11 with the respective clinical finding).
Tendons where TFRs had been identified at clinical examination
presented tenosynovitis in 10% of the cases, all of whom presented a
significantly increased retinaculum thickness (Table 1).
TABLE 1. Thickness of the retinacula in each investigated site and in tendons
presenting tendon friction rubs at physical examination









Healthy subjects (30) 0.8 (0.6–1.4) 0.8 (0.6–1.4) 0.8 (0.6–1.4) 0.8 (0.6–1.4)
Lc-SSc (28) 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.8 (0.6–1.4)
Dc-SSc TFRs (15) 0.8 (0.6–1.4) 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.8 (0.6–1.2)
Dc-SSc TFRsþ (12) 1.5 (1.1–2.3) 0.8 (0.6–1.4) 1.2 1.4 (1.1–2.0)
P * >0.05 >0.05 **
*P¼ 0.001, dcSSc TFRsþ vs HS; P¼0.002 dcSSc TFRsþ vs IcSSc; P¼0.001
dcSSc TFRþ vs dcSSc TFRs; * *P¼ 0.002, dcSSc TFRsþ vs HS; P¼ 0.003 dcSSc
TFRsþvs IcSSc; P¼0.003 dcSSc TFRsþ vs dcSSc TFRs.
Conclusion. US revealed a higher prevalence of tendon involvement
with respect to clinical examination in patients with SSc. Increased
retinaculum thickness might be the morphological basis of TFRs,
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Introduction. Understanding the genetic architecture of scleroderma
(SSc) susceptibility is vital both in gene discovery and in determining
the influence of previously identified susceptibility variants. It is parti-
cularly important in understanding disease mechanism in a disease
with few therapies and great morbidity and mortality.
Methods. We selected 557 cases from the Australian Scleroderma
Cohort Study (ASCS), for genotyping with the Immunochip, a custom
Illumina Infinium genotyping array containing 196 524 rare and com-
mon variants shown to be important in a wide variety of autoimmune
disorders. A total of 4537 controls were taken from the 1958 British
Birth cohort. Genotype data were analysed with PLINK. Samples
and SNPs with low call rates were excluded, as were SNPs in Hardy–
Weinberg disequilibrium or with less than two occurrences of the minor
allele. Eigenstrat was used to analyse population structure. The final
data set consisted of 505 cases, 4491 controls and 146 867 SNPs.
Allelic association analyses were conducted using Fisher’s exact test.
Genotype clusters were manually examined for all associations of
P<105 since calling is difficult for some rare variants.
Results. Significant and suggestive associations were detected at
seven loci. Several of these have been previously implicated in
scleroderma susceptibility (HLA-DRB1 and STAT4) and several are
novel associations, including SNPs near PXK (P¼4.4 106) and
CFDP1(P¼ 2.6106).
The strongest associations were with SNPs in the Class II region of the
MHC. One of the most strongly associated SNPs [rs4639334;
P¼1.6 108; odds ratio (OR)¼1.8] is in linkage disequilibrium
(r2¼ 0.46) with the Class II allele HLA-DRB1*11:01. This allele has
been associated with SSc. Another strongly associated SNP is
rs2857130 (P¼1.6 108; OR¼ 0.67), which lies in the promoter
region of HLA-DRB1, but is not in LD with any classical MHC alleles.
Outside the MHC, there were six regions of association with
P<105,including the confirmed SSc locus at STAT4. Several SNPs
implicate a locus at PXK, which has been previously associated with
SLE but not with SSc. The remaining associations are novel for both
SSc and SLE and require replication. Of particular interest is a rare
variant located within a non-coding RNA on chromosome 6q21 which
was 20 times more frequent in cases than controls. We are currently
dissecting the potential biological implications of this locus.
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Conclusions. This pilot study has confirmed previously reported SSc
associations, revealed further genetic overlap between SSc and SLE,
and identified putative novel SSc susceptibility loci including a rare
allele with major effect size.
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Fibrosis represents a common pathway leading to organ failure and
death in many diseases, including scleroderma, and has no effective
therapy. Dysregulated repair and excessive tissue scarring provides a
unifying mechanism for pathological fibrosis. The protein phosphatase
and tensin homologue (PTEN) dephosphorylates proteins that promote
tissue repair and thus could be a key fibrogenic mediator. PTEN
expression is reduced in skin fibroblasts from patients with the fibrotic
autoimmune disease diffuse SSc (dSSc) (n¼6, P<0.05). To evaluate
whether this deficiency could be sufficient for fibrogenesis in vivo,
we used a conditional knockout strategy to deleted PTEN in adult
mouse fibroblasts. Compared with littermate control mice, loss of
PTEN resulted in a 1.5-fold increase in dermal thickness due to excess
deposition of collagen and the presence of myofibroblasts (n¼6,
P<0.05). Moreover, lung fibrosis was also observed, including an
increase in collagen production and the presence of myofibroblasts
(n¼ 6, P<0.05). PTEN-deleted skin and lung fibroblasts showed
increased expression of connective tissue growth factor (CTGF/
CCN2). Overexpression of PTEN reduced the overexpression of
Type I collagen and CCN2 by dSSc fibroblasts (n¼3, P<0.05).
Double CCN2/PTEN mice did not get fibrosis; i.e. the absence of
CCN2 rescued the effects of loss of PTEN in terms of collagen and
myofibroblast production (n¼6, P<0.05). Loss of PTEN resulted in
increased expression of the proliferative marker PCNA; the loss of
CCN2 did not resuce this phenotype (n¼6, P<0.05). Thus, PTEN
appears to be a potential in vivo master regulator of fibroproliferative
conditions. CCN2 appears to mediate the fibrotic (collagen, myofibro-
blast) but not proliferative (PCNA) effect of loss of PTEN. Thus, PTEN
agonists may represent therapies for fibroproliferative conditions,
whereas CCN2 inhibition may specifically affect the fibrotic component
of these diseases.
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Background. MicroRNAs (miRs) regulate many pathophysiological
processes. Our aim was to investigate miR expression and function
in SSc.
Materials and methods. A total of 377 miRs were profiled on three
pooled SSc and healthy control (HC) fibroblasts by low-density array.
Differentially expressed miRs were further investigated in 12 individual
SSc and 6 HC fibroblasts by real-time PCR. MiR-145 expression was
also investigated in 12 individual and 6 HC dermis samples. miR-145
targets were analysed under pre/anti-miR transfection in SSc and HC
fibroblasts by real-time PCR and western blot.
Results. Twenty-six miRs were down-regulated and five up-regulated
in pooled SSc fibroblasts. Basal down-regulation of miR-17-5p, miR-
20a, miR-21, miR-24, miR-29a, miR-29b, miR-29c, miR-99a, miR-145,
miR-186 and miR-193b, as well as miR-155 up-regulation (all P< 0.05)
was confirmed in individual SSc fibroblasts. MiRs were regulated by
multiple factors in SSc fibroblasts: hypoxia exposure induced miR-210
up-regulation (P<0.05), while pro-fibrotic cytokines (TGF-b, PDGF-B
and IL-4) further reduced miR-29a/b/c levels (P< 0.05). MiR-145
expression was modulated by epigenetic modifications, as inhibition of
DNA methyltransferases by 5aza-C increased miR-145 levels by 25%
in SSc fibroblasts. Both miR-145 and its primary transcript pri-miR-145
were also down-regulated in SSc dermis (P<0.001) suggesting
transcriptional regulation. MiR-145 was further investigated for effects
on pro-fibrotic pathways: the miR-145 targets TGFBR2, SMAD3 and
CTGF were decreased between 53% and 66% at both mRNA and
protein level after transfection with pre-miR-145. Collagen Types I and
III were similarly reduced. A reporter gene assay with the 30-UTR of
TGFBR2 showed reduction of the luciferase gene activity under miR-
145 treatment by 34% (P< 0.05) indicating direct regulation of
TGFBR2 by miR-145.
Conclusions. Our data show a profoundly impaired miR profile in SSc,
which is regulated by multiple factors including epigenetic modifica-
tions. By up-regulating multiple pro-fibrotic factors on the post-
transcriptional level, dysregulated miRs appear important molecular
players in fibrogenesis. In particular, down-regulation of miR-145
showed strong pro-fibrotic effects in SSc by inducing multiple
components of the TGF-b signalling pathway.
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Objective. We conducted global gene expression profiling to identify
transcripts in skin biopsy samples of patients with SSc that correlate
with severity of interstitial lung disease (ILD).
Methods. Skin biopsy samples were obtained from 52 patients
enrolled in the Genetic vs Environment in Scleroderma Outcome Study
(GENISOS). RNA was extracted, amplified and hybridized on Illumina
HumanHT-12 arrays. Skin transcript levels correlating with concomi-
tantly obtained per cent predicted forced vital capacity (FVC; a
validated surrogate with severity of ILD) were identified by quantitative
trait analysis.
The plasma level of a candidate gene (CCL2) identified by the skin
gene expression analysis was examined in all patients enrolled in the
GENISOS cohort (n¼ 266) to determine its correlation with FVC.
Results. Fifty-two patients (diffuse cutaneous involvement¼ 59%,
disease duration¼7.73 years, presence of ILD¼ 31%) were examined
by global gene expression profiling. There were 109 skin transcripts
that significantly correlated with FVC levels. We performed unsuper-
vised hierarchical clustering of SSc samples using this gene list (114
transcripts). As shown in Fig. 1, 87.5% (14/16) patients with an
FVC<70% clustered together (colour-coded yellow in Fig. 1) while the
majority of patients (21/36¼58%) with FVC>70% clustered in a
separate group (colour-coded purple in Fig. 2). Next, we modelled the
significantly over-expressed genes in patients with more severe ILD
(FVC<70%) in the Ingenuity Pathways Knowledge Base (v9.0). The
genes belonging to pathways involved in chemotaxis and adhesion of
inflammatory cells were significantly over-represented (P¼2.1 107).
These genes included CCL2, CCL4, CCL5, CXCR4, SELE (CD62E) and
SELP (CD62P).
CCL2 (MCP-1), a transcript closely correlating with FVC (r¼0.37;
P¼0.007) was selected for our confirmatory plasma studies in the
GENISOS cohort. CCL2 levels were determined in baseline plasma
samples in the GENISOS cohort (n¼266 disease duration <5 years).
The plasma CCL2 levels inversely correlated with the concomitantly
obtained FVC in the univariable analysis (r¼0.18, P¼0.008).
This relationship remained significant (P¼0.013) after adjustment for
potential confounding effect of gender, age, ethnicity, smoking status,
disease duration, disease type or treatment with immunosuppressive
agents. This indicates that higher CCL2 levels correlate with more
severe ILD in SSc.
Conclusion. Skin gene expression levels belonging to pathways
involved in chemotaxis and adhesion of inflammatory cells correlate
with severity of lung disease in SSc. This finding can lead to
identification of novel therapeutic targets and biomarkers for more
focused and effective treatment of SSc-ILD.
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Background. A high percentage of SSc patients develop interstitial
lung disease (ILD) during the course of the disease. Promising data
have recently shown that lung US (LUS) is able to detect ILD by the
evaluation of B-lines (previously called US lung comets), the
sonographic marker of pulmonary interstitial syndrome.
Objective. To evaluate whether LUS could be employed for an early
screening of ILD in patients with a very early diagnosis of SSc.
Methods. Sixty-eight consecutive SSc patients [65 females, mean age
51 (13) years] who underwent a clinically driven chest high-resolution
CT (HRCT) were evaluated by LUS for detection of B-lines. Among
them, 24 patients fulfilled the criteria for a Very Early Diagnosis of SSc
(VEDOSS).
Results. ILD was present at HRCT in 69% of the total population and
in 65% of the VEDOSS population. A significant positive linear
correlation was found between B-line numbers and the presence of
ILD at HRCT (r¼0.55; P< 0.001) in all patients. When considering only
the VEDOSS population, the concordance rate between the two
examinations was 88%, with a sensitivity of 96%, a negative predictive
value of 88%, specificity of 50% and positive predictive value of 78%.
Conclusions. ILD appears very early in SSc patients. Presence of B-
lines at LUS examination correlates with ILD at HRCT. LUS is very
sensitive to detect early ILD even in patients with very early diagnosis
of SSc. The use of LUS as a screening tool for ILD seems feasible to
guide further investigation with HRCT.
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Background. Pulmonary arterial hypertension and pulmonary fibrosis
are established prognostic determinants in patients with SSc.
Pulmonary hypertension [by pulmonary artery systolic pressure
(PASP)] and fibrosis (by B-lines, also called US lung comets) can be
measured in a one-stop shop with cardiac and lung US.
Purpose. To assess the prognostic value of B-lines and PASP in SSc.
Methods. A total of 68 SSc patients [age 56 (14) years, 63 females]
admitted to the Rheumatology Division of the University of Pisa were
evaluated with a comprehensive 2D and Doppler echocardiography,
and lung US with B-lines assessment. B-lines score of a patient was
obtained by summing the number of B-lines found on anterior and
posterior chest. PASP was calculated from the maximal velocity of
tricuspid regurgitation flow.
Results. During follow-up [median (interquartile range) 25 (21–31)
months], 23 events occurred: 4 deaths, 3 admissions for worsening
skin involvement and 16 for worsening dyspnoea. An ROC analysis
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
FIG. 1
ii17
